免疫检查点抑制剂的治疗开发。

Therapeutic Development of Immune Checkpoint Inhibitors.

机构信息

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, 200001, China.

Biologics Discovery, Shanghai ChemPartner Co., Ltd., 965 Halei Road. Building #10, Zhangjiang Hi-Tech Park, Shanghai, China.

出版信息

Adv Exp Med Biol. 2020;1248:619-649. doi: 10.1007/978-981-15-3266-5_23.

DOI:10.1007/978-981-15-3266-5_23

PMID:32185726

Abstract

Immune checkpoint blockade (ICB) has been proven to be an effective strategy for enhancing the effector activity of anti-tumor T cells, and checkpoint blockers targeting CTLA-4, PD-1, and PD-L1 have displayed strong and durable clinical responses in certain cancer patients. The new hope brought by ICB therapy has led to the boost in therapeutic development of ICBs in recent years. Nonetheless, the therapeutic efficacy of ICBs varies substantially among cancer types and patients, and only a proportion of cancer patients could benefit from ICBs. The emerging targets and molecules for enhancing anticancer immunity may bring additional therapeutic opportunities for cancer patients. The current challenges in the ICB therapy have been discussed, aimed to provide further strategies for maximizing the efficacy of ICB therapy.

摘要

免疫检查点阻断 (ICB) 已被证明是增强抗肿瘤 T 细胞效应活性的有效策略，针对 CTLA-4、PD-1 和 PD-L1 的检查点抑制剂在某些癌症患者中显示出了强大且持久的临床反应。ICB 治疗带来的新希望促使近年来 ICB 的治疗开发得到了推动。然而，ICB 的治疗效果在癌症类型和患者之间存在很大差异，只有一部分癌症患者能从 ICB 中受益。增强抗癌免疫的新靶点和分子可能为癌症患者带来额外的治疗机会。讨论了 ICB 治疗中当前面临的挑战，旨在为最大限度提高 ICB 治疗效果提供进一步的策略。